Q3 EPS Forecast for Mirum Pharmaceuticals Reduced by Analyst

Posted by Stanley Muller on Oct 13th, 2026

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) – Research analysts at HC Wainwright reduced their Q3 2027 earnings per share estimates for Mirum Pharmaceuticals in a report released on Monday, October 12th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.27 per share for the quarter, down from their prior forecast of $0.35. HC Wainwright has a “Buy” rating and a $200.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.31) per share.

A number of other research analysts have also recently commented on the stock. Morgan Stanley upped their target price on shares of Mirum Pharmaceuticals from $137.00 to $152.00 and gave the company an “overweight” rating in a research report on Monday. UBS Group set a $137.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. Robert W. Baird lifted their price target on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. Citigroup boosted their price target on shares of Mirum Pharmaceuticals from $160.00 to $184.00 and gave the company a “buy” rating in a research note on Monday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $146.12.

Get Our Latest Research Report on MIRM

Mirum Pharmaceuticals Stock Up 0.1%

Shares of MIRM opened at $86.06 on Tuesday. The firm has a market cap of $5.59 billion, a P/E ratio of -5.91 and a beta of 0.61. Mirum Pharmaceuticals has a 12-month low of $63.23 and a 12-month high of $130.00. The company’s 50-day moving average price is $94.71 and its 200 day moving average price is $100.95. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The business’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.12) earnings per share.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Jupiter Topco LLC purchased a new position in Mirum Pharmaceuticals in the second quarter valued at $691,672,000. BlackRock Inc. acquired a new position in Mirum Pharmaceuticals during the 2nd quarter worth $513,945,000. William Blair Investment Management LLC acquired a new position in Mirum Pharmaceuticals during the 2nd quarter worth $164,453,000. Janus Henderson Group PLC increased its holdings in Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after purchasing an additional 880,505 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in Mirum Pharmaceuticals during the 2nd quarter worth about $78,434,000.

Insider Activity

In related news, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the transaction, the chief executive officer owned 194,440 shares of the company’s stock, valued at approximately $19,187,339.20. This represents a 13.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 658 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $100.00, for a total value of $65,800.00. Following the transaction, the senior vice president directly owned 616 shares in the company, valued at approximately $61,600. The trade was a 51.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 98,499 shares of company stock valued at $9,797,834. 8.32% of the stock is currently owned by corporate insiders.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

Positive Sentiment: Phase 3 EXPAND study met its primary endpoint. Mirum said LIVMARLI demonstrated a statistically significant treatment benefit in patients with ultra-rare cholestatic liver diseases, including biliary atresia. The result strengthens the case for expanding LIVMARLI’s use beyond its current indications. Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study
Positive Sentiment: Mirum plans to submit an FDA filing in 2027. A regulatory application based on the positive results provides a potential future catalyst, although commercialization remains dependent on regulatory review and approval. Mirum Reports Positive Phase 3 LIVMARLI Results
Positive Sentiment: Analysts became more bullish. Citigroup raised its price target from $160 to $184 and assigned a Buy rating, while HC Wainwright increased its target from $195 to $200 and maintained a Buy rating. The targets imply substantial upside from the referenced share price and indicate increased confidence in Mirum’s pipeline and growth prospects.
Neutral Sentiment: Mirum hosted an investor call to discuss the EXPAND topline results, giving investors additional details on the trial and the planned regulatory path. Mirum Investor Call Announcement
Negative Sentiment: The FDA filing is not expected until 2027, leaving execution, regulatory and commercialization risks before the potential indication can generate revenue.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.